Implantable shunt devices and methods for draining cerebrospinal fluid from a patient's subarachnoid space include a shunt having opposed first and second ends, the second end being constructed to penetrate a wall of a sigmoid, transverse, straight, or sagittal sinus of the patient, a one-way valve, a hollow passageway extending between the second end and the one-way valve such that cerebrospinal fluid can be drained through the second end and out through the valve, and a mechanism coupled to the shunt and configured to anchor the shunt at a desired location proximal to the subarachnoid space.

Systems, devices, methods, and compositions are described for providing an actively controllable implant configured to, for example, monitor, treat, or prevent microbial growth or adherence to the implant.

A siphon guard includes a housing having an inlet and an outlet. A primary flow path is disposed within the housing and is in fluid communication with the inlet and the outlet. A secondary flow path is disposed within the housing and is in fluid communication with the inlet and the outlet. The secondary flow path has a higher resistance to fluid flow than the primary path. A valve is disposed within the primary flow path. The valve has a valve seat and a first ball and a second ball. The first ball is movable by gravity between a valve closed position, where the first ball is in contact with the valve seat, and a valve open position, where the first ball is spaced from the valve seat. The first ball is disposed between the second ball and the valve seat. The second ball is movable by gravity between a valve closed position and a valve opened position.

Apparatus and methods for accomplishing fluid drainage and localized cooling of the central nervous system broadly encompassing an intrathecal catheter assembly accomplishing drainage and cooling, and a console apparatus that may contain control, cooling, and drainage subsystems, and use thereof.

Methods and tools are disclosed for treating chronic fatigue syndrome and fibromyalgia in a patient by diverting cerebrospinal fluid from the cerebral ventricles or the spinal subarachnoid space of the patient.

A device for use in pressure sensing such as hydrocephalus shunts, having a housing enclosing a chamber with at least one port communicating with the chamber. A wall of the chamber includes a flexible portion or thin diaphragm that deflects with transitions in pressure to contact an upstand structure of the housing. A pressure sensor is contained within an enclosure sealed from the chamber by a flexible membrane and which receives fluid pressure from the chamber. This arrangement allows for calibration of the device by identifying a knee feature in pressure data associated with the diaphragm making contact with the upstand.

Drainage systems for excess body fluids and associated methods are disclosed herein. A drainage system in accordance with an embodiment of the present technology can include, for example, a drainage catheter, a first reference line, a second reference line, and a pressure sensor assembly. The catheter can include a flexible interface member and an inlet can be placed in fluid communication with a site of excess body fluid within a patient. A first flexible region of the first reference line can be in pressure communication with the flexible interface member, and a second flexible region of the second reference line can be in pressure communication with the surrounding atmosphere. The pressure sensor assembly can be spaced apart from the flexible regions, and measure the pressures of the first and second reference lines. This information can be used to determine the pressure at the site of excess body fluid.

A subcutaneous implantable device has one or more adjustable settings with a setting device configured to selectively change between the one or more adjustable settings. An indicator, having an ultrasound reflection enhancement, indicates each particular setting of the one or more adjustable settings.

The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.

The present disclosure provides uses of TRPV4 antagonists in the treatment or prevention of hydrocephalus symptoms, also known as hydrocephaly, including hydrocephalus as a result of any structural defect, any metabolic defect, any injury (direct force to the head, indirect force to the head, shock waves, pressure changes, etc.), any insult (microbial, chemical, toxins, allergic reactions or other inflammatory process, or other pathology, e.g. cancer, benign tumor, etc.). Related materials and methods are also provided herein.